drugset / Trial / NCT01240824
Study of BCG + Aminophylline Toxicity When Used in the Treatment of Bladder Cancer
NaSingle-groupOpen-label
Summary
The purpose of this study is to evaluate whether a new potential treatment for non invasive bladder cancer is safe and if it leads to side effects such as irregular heart rate, agitation, or burning with urination. Patients who have early stage bladder cancer and will be receiving BCG, a bladder cancer therapy as recommended by a doctor, will be asked to participate in a study where they are given the standard BCG followed by the experimental drug, aminophylline. Although we hope this medicine may one day prove to help bladder cancer patients, at the current time we do not know if it has any benefits at all. We have data in mice that suggest that aminophylline slows the growth of tumors when coupled with BCG.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aminophylline | Small molecule | 3 mg/kg | Other |
| Subject | Aminophylline | Small molecule | 6 mg/kg | Other |
| Subject | Aminophylline | Small molecule | 9 mg/kg | Other |